

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* FCPR VENTECH B  (Last) (First) (Middle) 47 AVENUE DE L'OPERA  (Street) PARIS CEDEX 07, 10 75002  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/12/2015	3. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]	
		4. Relationship of Reporting Person(s) to Issuer  (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	5. If Amendment, Date Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(1)	Common Stock	400,573	\$ (2)	D	
Series B Preferred Stock	(1)	(1)	Common Stock	11,801	\$ (3)	D	
Series C Preferred Stock	(1)	(1)	Common Stock	17,363	\$ (4)	D	
Series D Preferred Stock	(1)	(1)	Common Stock	140,685	\$ (5)	D	
Common Stock Warrants (right to buy)	01/01/2015	06/06/2019	Common Stock	15,668	\$ (6)	D	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
FCPR VENTECH B 47 AVENUE DE L'OPERA PARIS CEDEX 07, 10 75002		X		

## Signatures

/s/ Alain Caffi, Chairman of Managing Board*	02/12/2015
**Signature of Reporting Person	Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The Issuer's Preferred Stock is convertible into Common Stock at any time at the holder's election. There is no expiration date for any series of Preferred Stock.
- (2) All outstanding shares of the Issuer's Series A Preferred Stock will automatically convert on a 10.94-for-one basis into Common Stock as shown in column 3 immediately upon the closing of the Issuer's initial public offering, for no additional consideration.
- (3) All outstanding shares of the Issuer's Series B Preferred Stock will automatically convert on a 10.94-for-one basis into Common Stock as shown in column 3 immediately upon the closing of the Issuer's initial public offering, for no additional consideration.
- (4) All outstanding shares of the Issuer's Series C Preferred Stock will automatically convert on a 9.60-for-one basis into Common Stock as shown in column 3 immediately upon the closing of the Issuer's initial public offering, for no additional consideration.
- (5) All outstanding shares of the Issuer's Series D Preferred Stock will automatically convert on a 10.96-for-one basis into Common Stock as shown in column 3 immediately upon the closing of the Issuer's initial public offering, for no additional consideration.
- (6) The per-share exercise price will be equal to the price per share at which shares of Common Stock are sold to the public pursuant to the Company's initial public offering.

**Remarks:**

\*Signed under power of attorney on behalf of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.